Pregnancy Drug is Causing Grown Daughters to Face Risk of Cancer, Infertility

|

The daughters of women given diethylstilbestrol (DES), a drug commonly used decades ago to prevent miscarriages and birth defects, are showing high rates of breast cancer and infertility problems, according to recent research. 

DES was removed from the market in 1971, after studies found that it was ineffective and appeared to be linked to vaginal cancer. However, for several decades, women were given the drug during pregnancy to prevent complications.

Grown daughters of those women are now showing increased rates of breast cancer, infertility and other health problems, according to a study published in the New England Journal of Medicine.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

Researchers looked at data on 4,653 women who were exposed in utero to DES and compared them to 1,927 women who were not exposed. They found that women whose mothers took DES faced double the risk of breast cancer and infertility, eight times the risk of miscarriage in the second trimester, triple the risk of stillbirth and increased chances of spontaneous abortion, ectopic pregnancy, preeclampsia and early menopause.

The research, funded by the National Cancer Institute, determined that daughters were at a high lifetime risk of a broad spectrum of DES side effects.

DES was a synthetic estrogen given to women as pills, topical creams and in other forms. It was in use from the 1940s until the 1971 DES recall and an estimated 4 million people are suspected to have been exposed to it in utero before use was discontinued.

The estimated 2 million men who were born to mothers using DES show some signs of increased risk of testicular problems and cysts, but at nowhere near the rate of problems suffered by women given DES, who are now in their 40s or older. The side effects of DES appear to be manifesting in granddaughters of users as well, with increased rates of late onset of menstruation and irregular menstrual cycles.


0 Comments


Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

MORE TOP STORIES

Six women have filed a joint, multiplaintiff BioZorb tissue marker lawsuit, all indicating that they suffered injuries and complications due to the recalled device’s defective design.
A federal judge has agreed to stay all case-specific discovery deadlines in Paraquat lawsuits, while the parties work to hammer out a settlement agreement to resolve thousands of claims.